AbbVie submits BLA to FDA for etentamig in relapsed or refractory multiple myeloma

AbbVie announced it submitted a Biologics License Application to the FDA for etentamig, a second-generation BCMA x CD3 bispecific T-cell engager administered intravenously, for adults with relapsed or refractory multiple myeloma. The submission is based on clinical data evaluating the treatment's efficacy and safety.

Detected & updated continuously · Source: Nebula